Friday, July 4, 2025 7/4/2025

The Cancer Cell Map Initiative v2.0

Award Number: U54CA274502
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/14/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

The Cancer Cell Map Initiative v2.0 - THE CANCER CELL MAP INITIATIVE v2.0 OVERALL SUMMARY The Cancer Genome Atlas and sister projects have now sequenced over 20,000 tumor genomes, providing a catalog of gene mutations, copy number variants and other genetic alterations associated with cancer. These data have made it clear that every cancer is a distinct genetic disease, with tumors that look physiologically similar often driven by patterns of gene mutations that are strikingly different. Due to this molecular heterogeneity, it is typically unclear what are the key driver mutations or dependencies in a given cancer and how these influence pathogenesis and response to therapy. One key observation for interpreting tumor genomes is that the many rare tumor mutations can be shown to converge on common molecular networks. Based on this premise we created the Cancer Cell Map Initiative (CCMI), whose mission is to create comprehensive maps of cancer molecular networks and to use these maps in intelligent systems for personalized therapy. In 2017, the CCMI was funded as an NCI U54 Research Center for Cancer Systems Biology, integrating expertise in network mapping, bioinformatic analysis and cancer research from leading academic laboratories at two University of California campuses (UCSF and UCSD). We have since generated comprehensive networks of protein interactions in breast and head-and-neck tumor cells and, from these data, identified several hundred protein complexes under selective mutational pressure in cancer (NeST v1.0). We have piloted deep learning systems (DCell, DrugCell and TCRP) that can use this protein network information to translate a patient’s tumor mutation profile to a predicted drug response, including FDA-approved and exploratory agents. We have implemented a rich portfolio of training opportunities and, leveraging UC institutional support, expanded the CCMI consortium to include more than a dozen faculty at UC and, most recently, Stanford. In the next five years, the CCMI will seek to: (1) Generate comprehensive protein interaction networks centered on key cancer driver genes in lung squamous cells (in healthy and diseased states) as well as the PIK3CA and TP53 pathways, which are central to many tumor types; (2) Systematically extend the CCMI collection of cancer protein interaction data with protein immunofluorescent imaging and cryo-electron microscopy to formulate multi-scale cancer cell maps; (3) Dissect the functional logic of these networks and maps by systematic genetic screening experiments in the same tumor types and pathways, using a panel of scalable cell proliferation, phenotype and pathway readouts; (4) Significantly advance and harden our DrugCell interpretable deep learning system for cancer precision medicine; (5) Train the current and next generation of scientists in network biology and its applications to cancer research; and (6) Continue to build a cadre of leading investigators to expand CCMI into a global coordinated partnership.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Centers Support Grants	000	3	4/11/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $2,259,341 )
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Centers Support Grants	002	3	8/13/2024	NON-COMPETING CONTINUATION	$2,259,341
2024	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Centers Support Grants	001	2	4/30/2024	NON-COMPETING CONTINUATION	$0
2024	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Centers Support Grants	000	2	4/8/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,259,341

Issue Date FY: 2023 ( Subtotal = $2,473,686 )
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Centers Support Grants	000	2	8/21/2023	NON-COMPETING CONTINUATION	$2,321,411
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Centers Support Grants	001	2	8/29/2023	SUPPLEMENT FOR EXPANSION	$152,275
														Subtotal = $2,473,686

Issue Date FY: 2022 ( Subtotal = $2,376,522 )
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Centers Support Grants	000	1	9/14/2022	NEW	$2,376,522
														Subtotal = $2,376,522

Grand Total All Awards = $7,109,549

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Cancer Cell Map Initiative v2.0

Award Number: U54CA274502

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/14/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer